Maze Therapeutics, Inc. (MAZE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$199.9M
Cash & Equivalents
$39.1M
Quarterly Burn Rate
15 mo
Est. Cash Runway
$1,692M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03732794 | AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment | OTHER | Active Not Recruiting | 150 |
| NCT06959121 | CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation | OTHER | Recruiting | 135 |
| NCT05267535 | Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease | PHASE3 | Active Not Recruiting | 225 |
| NCT01878617 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | PHASE2 | Active Not Recruiting | 660 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.